KATZUNG'S BASIC AND
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is teaching a group of students about how new
medications become available for patient use. Which statement
by a student demonstrates an accurate understanding of the
drug development process?
A. A medication is routinely marketed after laboratory testing if
it shows promising results.
B. Human clinical studies are conducted before laboratory and
animal testing.
C. Multiple phases of clinical research are typically completed to
evaluate safety and effectiveness before regulatory approval.
D. A medication can be approved without evidence of
therapeutic benefit if it appears safe.
Correct Answer: C
Rationale:
Clinical drug development generally progresses through
multiple phases of human research to evaluate safety, dosing,
effectiveness, and adverse effects before regulatory review and
potential approval. This systematic process helps protect
patients while establishing the medication's benefits and risks.
Laboratory and animal studies precede human testing, making
option B incorrect. Option A is incorrect because promising
laboratory findings alone are insufficient for marketing
,approval. Option D is incorrect because evidence of therapeutic
benefit is generally required in addition to acceptable safety.
Question 2
A patient asks why a newly prescribed medication is considered
"investigational." Which response by the nurse is most
appropriate?
A. "The medication has completed all required studies and is
available without restrictions."
B. "The medication is still being studied to better understand its
safety or effectiveness for specific uses."
C. "The medication is no longer monitored after patients begin
taking it."
D. "The medication has been shown to be completely free of
adverse effects."
Correct Answer: B
Rationale:
An investigational medication is still undergoing evaluation to
determine its safety, effectiveness, dosing, or appropriate
patient population. Patients receiving investigational drugs are
typically monitored closely. Option A describes an approved
medication rather than an investigational one. Option C is
incorrect because ongoing monitoring is essential during clinical
, studies. Option D is incorrect because no medication is
completely free of adverse effects.
Question 3
A nurse is reviewing a provider's medication order and notes
that the prescribed drug has a narrow therapeutic index. Which
nursing action is the highest priority?
A. Encourage the patient to discontinue the medication if minor
side effects occur.
B. Monitor recommended laboratory values and assess for signs
of toxicity.
C. Double the dose if the patient's symptoms persist.
D. Administer the medication only at bedtime.
Correct Answer: B
Rationale:
Drugs with a narrow therapeutic index have a small margin
between therapeutic and toxic concentrations. Careful
assessment, laboratory monitoring when indicated, and
observation for adverse effects are essential nursing
responsibilities. Option A could place the patient at risk by
discontinuing therapy without provider guidance. Option C is
unsafe because dosage adjustments require clinical evaluation.
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is teaching a group of students about how new
medications become available for patient use. Which statement
by a student demonstrates an accurate understanding of the
drug development process?
A. A medication is routinely marketed after laboratory testing if
it shows promising results.
B. Human clinical studies are conducted before laboratory and
animal testing.
C. Multiple phases of clinical research are typically completed to
evaluate safety and effectiveness before regulatory approval.
D. A medication can be approved without evidence of
therapeutic benefit if it appears safe.
Correct Answer: C
Rationale:
Clinical drug development generally progresses through
multiple phases of human research to evaluate safety, dosing,
effectiveness, and adverse effects before regulatory review and
potential approval. This systematic process helps protect
patients while establishing the medication's benefits and risks.
Laboratory and animal studies precede human testing, making
option B incorrect. Option A is incorrect because promising
laboratory findings alone are insufficient for marketing
,approval. Option D is incorrect because evidence of therapeutic
benefit is generally required in addition to acceptable safety.
Question 2
A patient asks why a newly prescribed medication is considered
"investigational." Which response by the nurse is most
appropriate?
A. "The medication has completed all required studies and is
available without restrictions."
B. "The medication is still being studied to better understand its
safety or effectiveness for specific uses."
C. "The medication is no longer monitored after patients begin
taking it."
D. "The medication has been shown to be completely free of
adverse effects."
Correct Answer: B
Rationale:
An investigational medication is still undergoing evaluation to
determine its safety, effectiveness, dosing, or appropriate
patient population. Patients receiving investigational drugs are
typically monitored closely. Option A describes an approved
medication rather than an investigational one. Option C is
incorrect because ongoing monitoring is essential during clinical
, studies. Option D is incorrect because no medication is
completely free of adverse effects.
Question 3
A nurse is reviewing a provider's medication order and notes
that the prescribed drug has a narrow therapeutic index. Which
nursing action is the highest priority?
A. Encourage the patient to discontinue the medication if minor
side effects occur.
B. Monitor recommended laboratory values and assess for signs
of toxicity.
C. Double the dose if the patient's symptoms persist.
D. Administer the medication only at bedtime.
Correct Answer: B
Rationale:
Drugs with a narrow therapeutic index have a small margin
between therapeutic and toxic concentrations. Careful
assessment, laboratory monitoring when indicated, and
observation for adverse effects are essential nursing
responsibilities. Option A could place the patient at risk by
discontinuing therapy without provider guidance. Option C is
unsafe because dosage adjustments require clinical evaluation.
